Keyphrases
2′-Deoxyguanosine
85%
Anti-tumor Response
14%
Antitumor Efficacy
14%
Cancer Dependency
14%
Cancer Initiating Cells
100%
Cancer Xenograft Model
14%
CD133
14%
Derived Model
14%
Effective Treatment
14%
Host Immune Response
14%
Humanized
14%
Immune Enhancement
14%
In Vitro Tumor Models
14%
Inhibit Tumor
14%
Innovative Therapies
14%
Intermittent Dose
14%
Irradiation
14%
L1 Cell Adhesion Molecule (L1CAM)
14%
Metastasis
14%
Metastatic Burden
14%
Nucleoside Analogues
14%
Phase II Clinical Trial
14%
Potential Therapeutics
14%
Reduction Effect
14%
Small Cell Lung Cancer
100%
STING Signaling
14%
Syngeneic
14%
Targeted Drugs
100%
Telomerase
28%
Telomerase Activity
28%
Telomere
100%
Telomere Dysfunction
14%
Therapeutic Approaches
14%
Therapeutic Target
14%
Thio
85%
Tumor Cells
14%
Tumor Growth
14%
Tumor Immunity
100%
Tumor-immune System
14%
Type I Interferon Signaling
14%
Biochemistry, Genetics and Molecular Biology
CD133
16%
Clinical Trial
16%
Deoxyguanosine
100%
Drug Targeting
100%
Enzyme
16%
Immunocompetent Cell
16%
interferon
16%
Mouse
16%
Nucleoside Analogue
16%
Syngenic
16%
Telomerase
66%
Telomere
100%
Tumor Immunity
100%
Tumor Progression
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
14%
Deoxyguanosine
85%
Drug Delivery System
100%
Interferon Type I
14%
Malignant Neoplasm
100%
Mouse
14%
Neoplasm
100%
Nucleoside Analog
14%
Small Cell Lung Cancer
100%
Telomerase
57%
Tumor Growth
14%
Immunology and Microbiology
Drug Targeting
100%
Immunocompetent Cell
33%
interferon
33%
Mouse
33%
Syngenic
33%
Telomere
100%
Tumor Cell
33%
Tumor Immunity
100%
Xenograft
33%